Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
Becker's Hospital Review1d
FDA to weigh approval of pain pill billed as opioid alternative
The FDA is set to consider approval of an alternative to opioids developed by Vertex Pharmaceuticals, The Washington Post reported Jan. 13.
Billed as nonaddictive, new pain pill could soon win FDA approval
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Hosted on MSN1d
New Painkiller May Be 'Landmark Development'
The FDA is expected to grant approval to a new pain medication with big potential—mainly because it's a non-opioid and is ...
kffhealthnews1d
FDA Might Soon Weigh Approval Of Pain Pill To Replace Addictive Opioids
Vertex Pharmaceuticals has a new drug called suzetrigine that it says is nonaddictive and would offer an alternative to painkillers such as oxycodone. The company’s application is pending before the ...
Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will ...
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
NDAQ:VRTX) Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud ...
Vertex Pharmaceuticals: Hold Rating Amid Mixed Results for Suzetrigine in LSR and Optimistic Prospects in Acute Pain
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...